Table 3.
ODMT discontinuation rates at cumulative post-index time windows of within 3, 6, 9, and 12 months. Because patients had varying durations in their time of follow-up, sample sizes were different for each time window. P-values for medication switching, dose reduction, re-starts, and add-ons were indeterminate, therefore, these data are not shown
| Prescribing parameters, n (%) | Total | FTY | DMF | TFN | P-value (3 groups) |
|---|---|---|---|---|---|
| (N = 293) | (N = 101) | (N = 133) | (N = 59) | ||
| Within 3 months | |||||
| Patients, n | 281 | 98 | 124 | 59 | |
| Discontinuation | 12 (4.3) | 5 (5.1) | 5 (4) | 2 (3.4) | 0.8629 |
| Within 6 months | |||||
| Patients, n | 236 | 79 | 106 | 51 | |
| Discontinuation | 18 (7.6) | 5 (6.3) | 6 (5.7) | 7 (13.7) | 0.177 |
| Within 9 months | |||||
| Patients, n | 188 | 63 | 85 | 40 | |
| Discontinuation | 25 (13.3) | 6 (9.5) | 12 (14.1) | 7 (17.5) | 0.4866 |
| Within 12 months | |||||
| Patients, n | 151 | 55 | 65 | 31 | |
| Discontinuation | 22 (14.6) | 6 (10.9) | 9 (13.8) | 7 (22.6) | 0.3299 |
DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod, TFN teriflunomide